MPP urges FDA to “phase down” amalgam use

MPP recently provided testimony to an FDA panel charged with re-examining  dental amalgam.  We pointed out  that while FDA panel re-evalutates, the World Health Organization  is expected to recommend that amalgam use be “phased down.”   “We welcome WHO’s  support for “phase down” , and urge FDA to do the same,” said MPP’s director.   The WHO is expected to soon final its meeting report in preparation for the upcoming  International Negotiations Committee deliberations  in Chiba, Japan, 24-28 January, 2011, that will ultimately lead to the adoption of a legally binding instrument on mercury by 2013.